" Korean versions of Wegovy and Mounjaro are coming"... Hanmi Science Surges More Than 10% in After-Hours Trading
Hanmi Pharmaceutical's GLP-1 Obesity Drug Receives Product Approval
Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, is surging more than 10% in after-hours trading on Oct. 7.
As of 6:10 p.m. on Oct. 7, Hanmi Science was trading at 64,000 won, up 10.15% from its regular-session closing price of 58,100 won.
Hanmi Science is the operating holding company of the Hanmi Pharmaceutical Group, whose affiliates include Hanmi Pharmaceutical, Online Pharm, and JVM, a company specializing in automated pharmaceutical dispensing systems. Its main sources of revenue include managing affiliates, income from equity stakes, and patent and brand royalties. It also operates healthcare and pharmaceutical distribution businesses.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The stock is believed to be gaining after news broke that Epeoto Injector, a new GLP-1 obesity treatment developed in-house by Hanmi Pharmaceutical, received product approval from the Ministry of Food and Drug Safety. Hanmi Pharmaceutical is preparing to launch the drug with the goal of supplying it in South Korea by the end of the year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.